The global hepatitis C drug market was valued at USD 7.86 billion in 2018 and is expected to grow to USD 9.84 billion by 2032, registering a compound annual growth rate (CAGR) of 1.8% over the forecast period from 2018 to 2032. In 2018, North America led the market, accounting for 47.46% of the global share.
The Hepatitis C drug market is witnessing steady growth due to increasing awareness, rising diagnosis rates, and advancements in antiviral therapies. The market is primarily driven by the widespread adoption of direct-acting antiviral (DAA) drugs, which offer high cure rates, fewer side effects, and shorter treatment durations. Government initiatives, public health campaigns, and expanded screening programs are also contributing to market expansion, especially in developing regions. As patents for several branded drugs expire, the entry of cost-effective generics is expected to boost accessibility and treatment uptake. With continued innovation and global efforts to eliminate Hepatitis C, the market is poised for sustained development over the coming years.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562
Market Segmentation
The Hepatitis C drug market is segmented based on drug class into direct-acting antivirals, combination therapies, and others.
By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
Patient type segmentation includes acute and chronic hepatitis C cases, with chronic infections accounting for the majority of the demand.
The Hepatitis C drug market also segments drugs based on genotypes, with pan-genotypic regimens becoming increasingly dominant.
List of Companies Profiled:
AbbVie Inc.
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
F. Hoffmann-La Roche Ltd
Vertex Pharmaceuticals Incorporated
Other Prominent Players
Market Growth
The Hepatitis C drug market is experiencing steady growth driven by increased awareness, improved diagnostic rates, and advancements in antiviral treatment.
The introduction of highly effective direct-acting antivirals has transformed the landscape of the Hepatitis C drug market, leading to higher cure rates and shorter treatment durations.
Continued government initiatives and public health programs targeting hepatitis elimination are contributing to long-term market stability.
The Hepatitis C drug market is expected to maintain moderate growth due to consistent demand in both developed and developing regions.
Restraining Factors
High treatment costs continue to limit access to medications in low- and middle-income countries within the Hepatitis C drug market.
Limited awareness and lack of screening programs in certain regions hinder early diagnosis and treatment uptake.
The stigma associated with hepatitis infections may delay patient engagement with healthcare services.
Generic drug entry, while improving affordability, may impact the revenue growth of branded drug manufacturers in the Hepatitis C drug market.
Regional Analysis
North America holds a significant share of the Hepatitis C drug market, driven by strong healthcare infrastructure and established screening protocols.
Europe follows closely due to wide access to advanced therapies and comprehensive national treatment programs.
The Asia-Pacific region is emerging as a key growth area for the Hepatitis C drug market, fueled by expanding healthcare access and public awareness campaigns.
Latin America and the Middle East & Africa are witnessing gradual growth, supported by global health initiatives and increasing diagnosis rates.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045, Maharashtra, India.
Phone: U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com